In our study, we confirmed that RGS inhibited RAS signaling, but we did not investigate PLK1 kinase activity or microtubule dynamics in RGS-treated CRC samples; thus, our results could not eliminate the contribution of other signaling pathways. This evidence concerns the gene PLK1 and colorectal carcinoma.